Article

Tophi Defined: Neutrophil NETS, Out of Control

What actually are the tophi of gout? They are bits of blasted neutrophils with their feedback controls out of kilter, according to new research.

Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nature Medicine 20:511–517 (2014) doi:10.1038/nm.3547 Published online 28 April 2014

As they are being studied, neutrophil extracellular traps (NETs) are starting to resemble the tophi of gout, and gout is starting to resemble a defect in control of their inflammatory processes.

Neutrophils recruited to sites of inflammation undergo oxidative burst and produce reactive oxygen species. They eject chromatin, bactericidal molecules, and granular enzymes into the extracellular space to form NETs, which immobilize and kill extracellular pathogens.

At low densities, the neutrophils release pro-inflammatory mediators. But at high densities, the neutrophils release anti-inflammatory mediators that provide a negative feedback and control the process.

Neutrophils respond to pathogens, but monosodium urate (MSU) crystals can also induce neutrophilic inflammation and aggregation of NETs.

These researchers show that gouty tophi are composed of extended areas of extracellular DNA co-localizing with material from neutrophil granules. In gout patients the NET mechanism is impaired, they say, and thus the inflammation from MSU crystals is uncontrolled and persistent.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.